Hebei Changshan Biochem Pharma (300255) - Total Liabilities
Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) has total liabilities worth CN¥3.18 Billion CNY (≈ $465.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hebei Changshan Biochem Pharma - Total Liabilities Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma's total liabilities have evolved over time, based on quarterly financial data. See 300255 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Hebei Changshan Biochem Pharma Competitors by Total Liabilities
The table below lists competitors of Hebei Changshan Biochem Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
International Seaways Inc
NYSE:INSW
|
USA | $648.37 Million |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥1.14 Billion |
|
FADU Inc.
KQ:440110
|
Korea | ₩47.55 Billion |
|
Sichuan Chemical Co Ltd
SHE:000155
|
China | CN¥14.81 Billion |
|
Westgold Resources Ltd
AU:WGX
|
Australia | AU$1.32 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥1.86 Billion |
|
Cofinimmo SA
BR:COFB
|
Belgium | €2.88 Billion |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
China | CN¥3.29 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Hebei Changshan Biochem Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hebei Changshan Biochem Pharma market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hebei Changshan Biochem Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual total liabilities of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.99 Billion ≈ $437.10 Million |
+6.80% |
| 2023-12-31 | CN¥2.80 Billion ≈ $409.25 Million |
-6.20% |
| 2022-12-31 | CN¥2.98 Billion ≈ $436.33 Million |
+40.80% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.89 Million |
+23.17% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.59 Million |
+40.89% |
| 2019-12-31 | CN¥1.22 Billion ≈ $178.57 Million |
-7.68% |
| 2018-12-31 | CN¥1.32 Billion ≈ $193.42 Million |
+20.75% |
| 2017-12-31 | CN¥1.09 Billion ≈ $160.18 Million |
+29.92% |
| 2016-12-31 | CN¥842.59 Million ≈ $123.30 Million |
+11.30% |
| 2015-12-31 | CN¥757.07 Million ≈ $110.78 Million |
+22.53% |
| 2014-12-31 | CN¥617.87 Million ≈ $90.41 Million |
+71.74% |
| 2013-12-31 | CN¥359.78 Million ≈ $52.65 Million |
+22.89% |
| 2012-12-31 | CN¥292.77 Million ≈ $42.84 Million |
+47.29% |
| 2011-12-31 | CN¥198.78 Million ≈ $29.09 Million |
-5.91% |
| 2010-12-31 | CN¥211.25 Million ≈ $30.91 Million |
+97.15% |
| 2009-12-31 | CN¥107.15 Million ≈ $15.68 Million |
+3.87% |
| 2008-12-31 | CN¥103.16 Million ≈ $15.10 Million |
-- |
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more